Highlights

  • Total revenues rose 30% to USD 3.0 million driven by testing and pharma services.
  • Operational efficiencies and cost reductions cut underlying EBITDA loss by 54%.
  • Strategic collaborations with Tempus AI and MVP Health Care expand U.S. access.

Renalytix plc (LSE:RENX), a precision medicine diagnostics company, announced its audited results for the fiscal year ended 30 June 2025. The company reported total revenue of USD 3.0 million, up 30% from FY2024 (USD 2.3 million), supported by testing growth and increased pharmaceutical services revenue.

Margins improved through higher testing volumes and operational efficiencies, while administrative expense reductions, NASDAQ delisting, and regaining Foreign Private Issuer status contributed to a 54% decrease in underlying EBITDA loss. The company also received over USD 1 million in R&D tax credits for FY2024 and FY2023, including USD 0.4 million post year-end.

Renalytix completed an over-subscribed institutional equity fundraise of GBP 6.7 million in September 2025 and achieved a 50% reduction in laboratory test turnaround time.

Commercial Progress and Partnerships

During FY2025, Renalytix expanded its electronic medical record (EMR) integrated testing across healthcare networks. The first full year under Medicare reimbursement resulted in improved accounts receivable and average unit pricing. Integration with a large New York physician network validated the company’s model for scaling access through EMR systems.

In September 2025, Renalytix entered a collaboration with Tempus AI to integrate kidneyIntelX.dkd into Tempus’ precision medicine platform, enabling national availability. In August 2025, the company partnered with MVP Health Care, giving access to up to 770,000 members across New York and Vermont. Expansion into Arizona marked the company’s fourth U.S. target market alongside New York, Texas, and Florida.

CEO Statement

“FY2025 was a key year for establishing a solid pathway for testing adoption, life science services and strategic partnering,” said the CEO. “This was the first full year during which we had Medicare reimbursement coverage for our FDA prognostic blood test, kidneyintelX.dkd. We made advances in our pharma service business and have substantially restructured our operations around commercial capability for a significantly reduced cost base.”

Financial Stability and Pharma Collaborations

Renalytix strengthened its balance sheet through debt renegotiation in October 2024 and conversion of USD 4 million in convertible debt post year-end, leaving long-term debt at GBP 3.1 million as of October 2025. Administrative expenses declined over 40% year-on-year, reflecting operational optimization.

Service revenues from collaborations with AstraZeneca, Steno Diabetes Center, and The Joslin Diabetes Center increased more than 200% year-on-year. These programs continue to support kidneyIntelX technology in advancing drug development and therapy utility.

Outlook

The company plans to further integrate kidneyIntelX.dkd into EMR systems and expand through partnerships such as Tempus AI and MVP Health Care. Renalytix expects additional strategic collaborations in FY2026 and intends to host a capital markets day in Q3 FY2026 to present its commercial roadmap.

Share Performance

RENX’s shares traded at GBX 8.40 per share on 03 November 2025, up by 1.42% from its previous close of GBX 8.25.